Editas Medicine Inc. Company Profile
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Editas Medicine at a glance
Editas Medicine Inc. (NASDAQ: EDIT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Editas Medicine is led by Dr. Gilmore O'Neill M.D. and employs about 87 people. The company's shares have traded publicly since 2016.
At a market capitalization of $253.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001650664, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Editas Medicine do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Editas Medicine Inc.
- Ticker
- NASDAQ: EDIT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Gilmore O'Neill M.D.
- Employees
- 87
- Headquarters
- 11 Hurley Street, Cambridge, MA, United States
- Phone
- 617 401 9000
- Website
- editasmedicine.com
- IPO year
- 2016
- Market cap
- $253.12M
- SEC CIK
- 0001650664
- Latest annual report
- 10-K · Mar 9, 2026
Companies similar to Editas Medicine
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs EDIT |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs EDIT |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs EDIT |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs EDIT |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs EDIT |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs EDIT |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs EDIT |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs EDIT |